Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy
|
June 21, 2019
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
Mikael Dellborg, Marc P Bonaca, Robert F Storey, et al.
The New England Journal of Medicine
|
March 17, 2015
Long-term use of ticagrelor in patients with prior myocardial infarction
Marc P Bonaca, Deepak L Bhatt, Marc Cohen, et al.
European Journal of Heart Failure
|
December 28, 2020
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF
Pooja Dewan, Kieran F Docherty, Olof Bengtsson, et al.
European Journal of Heart Failure
|
July 17, 2021
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
Carly Adamson, Pardeep S Jhund, Kieran F Docherty, et al.
Journal of the American College of Cardiology
|
December 16, 2022
Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction
Mikhail N Kosiborod, Ankeet S Bhatt, Brian L Claggett, et al.
JACC. Heart Failure
|
February 7, 2021
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF
Li Shen, Søren Lund Kristensen, Olof Bengtsson, et al.
European Journal of Heart Failure
|
September 2, 2022
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF
Carly Adamson, Lorna M Cowan, Rudolf A de Boer, et al.
NEJM Evidence
|
February 6, 2024
Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials
Toru Kondo, Samvel B Gasparyan, Pardeep S Jhund, et al.
JAMA Cardiology
|
May 20, 2023
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial
Alexander Peikert, Alvin Chandra, Mikhail N Kosiborod, et al.
JAMA Cardiology
|
April 26, 2023
Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial
Pardeep S Jhund, Brian L Claggett, Atefeh Talebi, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
European Heart Journal. Cardiovascular Pharmacotherapy
|
June 21, 2019
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
Mikael Dellborg, Marc P Bonaca, Robert F Storey, et al.
The New England Journal of Medicine
|
March 17, 2015
Long-term use of ticagrelor in patients with prior myocardial infarction
Marc P Bonaca, Deepak L Bhatt, Marc Cohen, et al.
European Journal of Heart Failure
|
December 28, 2020
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF
Pooja Dewan, Kieran F Docherty, Olof Bengtsson, et al.
European Journal of Heart Failure
|
July 17, 2021
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
Carly Adamson, Pardeep S Jhund, Kieran F Docherty, et al.
Journal of the American College of Cardiology
|
December 16, 2022
Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction
Mikhail N Kosiborod, Ankeet S Bhatt, Brian L Claggett, et al.
JACC. Heart Failure
|
February 7, 2021
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF
Li Shen, Søren Lund Kristensen, Olof Bengtsson, et al.
European Journal of Heart Failure
|
September 2, 2022
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF
Carly Adamson, Lorna M Cowan, Rudolf A de Boer, et al.
NEJM Evidence
|
February 6, 2024
Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials
Toru Kondo, Samvel B Gasparyan, Pardeep S Jhund, et al.
JAMA Cardiology
|
May 20, 2023
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial
Alexander Peikert, Alvin Chandra, Mikhail N Kosiborod, et al.
JAMA Cardiology
|
April 26, 2023
Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial
Pardeep S Jhund, Brian L Claggett, Atefeh Talebi, et al.
Page
of 8